OPTI-AML Venetoclax Optimization
Blood Cancer United announced more than 50 ASCO and EHA 2026 abstracts, highlighted by an oral EHA presentation from the randomized Phase 2 OPTI-AML substudy evaluating reduced-duration venetoclax dosing with azacitidine in newly diagnosed…
